{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:10:56Z","timestamp":1781827856980,"version":"3.54.5"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018693","name":"Horizon Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"DFG","doi-asserted-by":"publisher","award":["FOR2879\/2"],"award-info":[{"award-number":["FOR2879\/2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Forschung, Technologie und Raumfahrt","doi-asserted-by":"publisher","award":["01EJ2205D"],"award-info":[{"award-number":["01EJ2205D"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association Inc","doi-asserted-by":"publisher","award":["23TPA1070711"],"award-info":[{"award-number":["23TPA1070711"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["777111"],"award-info":[{"award-number":["777111"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.biopha.2025.118762","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:11:25Z","timestamp":1763640685000},"page":"118762","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Revisiting soluble guanylate cyclase pharmacology: Additive potential of stimulators and activators"],"prefix":"10.1016","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1667-0266","authenticated-orcid":false,"given":"Alexandra","family":"Petraina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2437-1773","authenticated-orcid":false,"given":"Mahmoud H.","family":"Elbatreek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7940-4977","authenticated-orcid":false,"given":"Christopher T.","family":"Neullens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1318-8300","authenticated-orcid":false,"given":"Theodora","family":"Saridaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vu Thao-vi","family":"Dao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3071-4269","authenticated-orcid":false,"given":"Rebecca D.","family":"Szepanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9094-4165","authenticated-orcid":false,"given":"Emil","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5985-9261","authenticated-orcid":false,"given":"Wolfgang","family":"Sippl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0935-074X","authenticated-orcid":false,"given":"Ana I.","family":"Casas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald H.H.W.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118762_bib1","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(94)90267-4","article-title":"NO at work","volume":"78","author":"Schmidt","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2025.118762_bib2","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/nature12722","article-title":"Dysfunctional nitric oxide signalling increases risk of myocardial infarction","volume":"504","author":"Erdmann","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2025.118762_bib3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41540-017-0039-7","article-title":"A diseasome cluster-based drug repurposing of soluble guanylate cyclase activators from smooth muscle relaxation to direct neuroprotection","volume":"4","author":"Langhauser","year":"2018","journal-title":"NPJ Syst. Biol. Appl."},{"key":"10.1016\/j.biopha.2025.118762_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3000885","article-title":"NOX5-induced uncoupling of endothelial NO synthase is a causal mechanism and theragnostic target of an age-related hypertension endotype","volume":"18","author":"Elbatreek","year":"2020","journal-title":"PLoS Biol."},{"key":"10.1016\/j.biopha.2025.118762_bib5","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/cvr\/cvab240","article-title":"Cyclic GMP modulating drugs in cardiovascular diseases: mechanism-based network pharmacology","volume":"118","author":"Petraina","year":"2022","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.biopha.2025.118762_bib6","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/hmg\/ddu478","article-title":"Genome-wide association study in Chinese identifies novel loci for blood pressure and hypertension","volume":"24","author":"Lu","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.biopha.2025.118762_bib7","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/cge.12739","article-title":"Disrupted nitric oxide signaling due to GUCY1A3 mutations increases risk for moyamoya disease, achalasia and hypertension","volume":"90","author":"Wallace","year":"2016","journal-title":"Clin. Genet."},{"key":"10.1016\/j.biopha.2025.118762_bib8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.niox.2023.03.002","article-title":"NO binds to the distal site of haem in the fully activated soluble guanylate cyclase","volume":"134-135","author":"Liu","year":"2023","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.biopha.2025.118762_bib9","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1172\/JCI28371","article-title":"Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels","volume":"116","author":"Stasch","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2025.118762_bib10","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/CIRCULATIONAHA.105.581405","article-title":"Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling","volume":"113","author":"Dumitrascu","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2025.118762_bib11","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1209657","article-title":"CHEST-1 Study Group, Riociguat for the treatment of chronic thromboembolic pulmonary hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118762_bib12","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"PATENT-1 Study Group, Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118762_bib13","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1183\/09031936.00087114","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2)","volume":"45","author":"Simonneau","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.biopha.2025.118762_bib14","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"VICTORIA study group, vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118762_bib15","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.jacc.2020.08.031","article-title":"Targeting cyclic guanosine monophosphate to treat heart failure: JACC review topic of the week","volume":"76","author":"Emdin","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2025.118762_bib16","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1152\/physiol.00001.2013","article-title":"Modulation of soluble guanylate cyclase for the treatment of erectile dysfunction","volume":"28","author":"Lasker","year":"2013","journal-title":"Physiology"},{"key":"10.1016\/j.biopha.2025.118762_bib17","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/jsm.12846","article-title":"Oximes induce erection and are resistant to oxidative stress","volume":"12","author":"Pauwels","year":"2015","journal-title":"J. Sex. Med."},{"key":"10.1016\/j.biopha.2025.118762_bib18","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jsxm.2016.12.007","article-title":"Erectile dysfunction in heme-deficient nitric oxide-unresponsive soluble guanylate cyclase knock-in mice","volume":"14","author":"Decaluw\u00e9","year":"2017","journal-title":"J. Sex. Med."},{"key":"10.1016\/j.biopha.2025.118762_bib19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.freeradbiomed.2022.09.026","article-title":"Cigarette smoke induces pulmonary arterial dysfunction through an imbalance in the redox status of the soluble guanylyl cyclase","volume":"193","author":"Sevilla-Montero","year":"2022","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.biopha.2025.118762_bib20","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrd2038","article-title":"NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential","volume":"5","author":"Evgenov","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2025.118762_bib21","doi-asserted-by":"crossref","first-page":"8482","DOI":"10.1038\/ncomms9482","article-title":"Cardiovascular and pharmacological implications of haem-deficient NO-unresponsive soluble guanylate cyclase knock-in mice","volume":"6","author":"Thoonen","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118762_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.116739","article-title":"Runcaciguat activates soluble guanylyl cyclase via the histidine essential for heme binding and nitric oxide activation","volume":"232","author":"Wittrien","year":"2025","journal-title":"Biochem. Pharm."},{"key":"10.1016\/j.biopha.2025.118762_bib23","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1074\/jbc.M310141200","article-title":"Identification of residues crucially involved in the binding of the heme moiety of soluble guanylate cyclase","volume":"279","author":"Schmidt","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2025.118762_bib24","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/j.1476-5381.2009.00263.x","article-title":"Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation","volume":"157","author":"Hoffmann","year":"2009","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118762_bib25","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1161\/CIRCRESAHA.109.198234","article-title":"Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation","volume":"105","author":"Meurer","year":"2009","journal-title":"Circ. Res."},{"key":"10.1016\/j.biopha.2025.118762_bib26","doi-asserted-by":"crossref","first-page":"5492","DOI":"10.1038\/s41467-021-25617-0","article-title":"Activation mechanism of human soluble guanylate cyclase by stimulators and activators","volume":"12","author":"Liu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118762_bib27","doi-asserted-by":"crossref","first-page":"10848","DOI":"10.1021\/bi9929296","article-title":"Inhibition of soluble guanylate cyclase by ODQ","volume":"39","author":"Zhao","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.biopha.2025.118762_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0026-895X(25)09113-8","article-title":"Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase","volume":"50","author":"Schrammel","year":"1996","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2025.118762_bib29","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.bcp.2019.02.007","article-title":"A novel soluble guanylyl cyclase activator, BR 11257, acts as a non-stabilising partial agonist of sGC","volume":"163","author":"Elgert","year":"2019","journal-title":"Biochem. Pharm."},{"key":"10.1016\/j.biopha.2025.118762_bib30","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1124\/mol.117.109918","article-title":"Irreversible activation and stabilization of soluble guanylate cyclase by the protoporphyrin IX mimetic cinaciguat","volume":"93","author":"Kollau","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2025.118762_bib31","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/978-3-540-68964-5_14","article-title":"NO- and haem-independent soluble guanylate cyclase activators","author":"Schmidt","year":"2009","journal-title":"Handb. Exp. Pharm."},{"key":"10.1016\/j.biopha.2025.118762_bib32","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1016\/j.febslet.2006.06.079","article-title":"Identification of residues crucially involved in soluble guanylate cyclase activation","volume":"580","author":"Rothkegel","year":"2006","journal-title":"FEBS Lett."},{"key":"10.1016\/j.biopha.2025.118762_bib33","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/35065611","article-title":"NO-independent regulatory site on soluble guanylate cyclase","volume":"410","author":"Stasch","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2025.118762_bib34","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1124\/mol.56.2.243","article-title":"The soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3,-a] quinoxalin-1-one is a nonselective heme protein inhibitor of nitric oxide synthase and other cytochrome P-450 enzymes involved in nitric oxide donor bioactivation","volume":"56","author":"Feelisch","year":"1999","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2025.118762_bib35","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1021\/bi972686m","article-title":"Identification of histidine 105 in the beta1 subunit of soluble guanylate cyclase as the heme proximal ligand","volume":"37","author":"Zhao","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.biopha.2025.118762_bib36","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1073\/pnas.91.7.2592","article-title":"Mutation of His-105 in the beta 1 subunit yields a nitric oxide-insensitive form of soluble guanylyl cyclase","volume":"91","author":"Wedel","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2025.118762_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2019.113065","article-title":"Thermal shift assay: Strengths and weaknesses of the method to investigate the ligand-induced thermostabilization of soluble guanylyl cyclase","volume":"181","author":"Elgert","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.biopha.2025.118762_bib38","doi-asserted-by":"crossref","first-page":"10763","DOI":"10.1073\/pnas.190333697","article-title":"Human recombinant soluble guanylyl cyclase: expression, purification, and regulation","volume":"97","author":"Lee","year":"2000","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biopha.2025.118762_bib39","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12917-020-02451-y","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research","volume":"16","author":"Percie du Sert","year":"2020","journal-title":"BMC Vet. Res."},{"key":"10.1016\/j.biopha.2025.118762_bib40","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1177\/0271678X17709185","article-title":"The IMPROVE guidelines (Ischaemia Models: Procedural Refinements Of in Vivo Experiments)","volume":"37","author":"Percie du Sert","year":"2017","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"10.1016\/j.biopha.2025.118762_bib41","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0022-1759(86)90368-6","article-title":"Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability","volume":"89","author":"Denizot","year":"1986","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.biopha.2025.118762_bib42","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2210-9-S1-S41","article-title":"NO-insensitive sGCbeta1 H105F knockin mice: if NO has no place to go","volume":"9","author":"Thoonen","year":"2009","journal-title":"BMC Pharm."},{"key":"10.1016\/j.biopha.2025.118762_bib43","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1523\/JNEUROSCI.14-01-00134.1994","article-title":"Extracellular cGMP in the hippocampus of freely moving rats as an index of nitric oxide (NO) synthase activity","volume":"14","author":"Vallebuona","year":"1994","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2025.118762_bib44","doi-asserted-by":"crossref","first-page":"F697","DOI":"10.1152\/ajprenal.00003.2020","article-title":"Praliciguat inhibits progression of diabetic nephropathy in ZSF1 rats and suppresses inflammation and apoptosis in human renal proximal tubular cells","volume":"319","author":"Liu","year":"2020","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.biopha.2025.118762_bib45","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.1021\/acs.jmedchem.7b00449","article-title":"Discovery of the soluble guanylate cyclase stimulator vericiguat (BAY 1021189) for the treatment of chronic heart failure","volume":"60","author":"Follmann","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2025.118762_bib46","series-title":"New Approaches to Drug Discovery","author":"Nielsch","year":"2016"},{"key":"10.1016\/j.biopha.2025.118762_bib47","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1021\/bi4015133","article-title":"YC-1 binding to the \u03b2 subunit of soluble guanylyl cyclase overcomes allosteric inhibition by the \u03b1 subunit","volume":"53","author":"Purohit","year":"2014","journal-title":"Biochemistry"},{"key":"10.1016\/j.biopha.2025.118762_bib48","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41586-019-1584-6","article-title":"Structural insights into the mechanism of human soluble guanylate cyclase","volume":"574","author":"Kang","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2025.118762_bib49","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1089\/ars.2016.6693","article-title":"Structure and activation of soluble guanylyl cyclase, the nitric oxide sensor","volume":"26","author":"Montfort","year":"2017","journal-title":"Antioxid. Redox Signal"},{"key":"10.1016\/j.biopha.2025.118762_bib50","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1021\/acs.biochem.3c00052","article-title":"Role of the coiled-coil domain in allosteric activity regulation in soluble guanylate cyclase","volume":"62","author":"Wittenborn","year":"2023","journal-title":"Biochemistry"},{"key":"10.1016\/j.biopha.2025.118762_bib51","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.50634","article-title":"Allosteric activation of the nitric oxide receptor soluble guanylate cyclase mapped by cryo-electron microscopy","volume":"8","author":"Horst","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.biopha.2025.118762_bib52","doi-asserted-by":"crossref","first-page":"21602","DOI":"10.1073\/pnas.0911083106","article-title":"A nitric oxide\/cysteine interaction mediates the activation of soluble guanylate cyclase","volume":"106","author":"Fernhoff","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biopha.2025.118762_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143523","article-title":"Mapping soluble guanylyl cyclase and protein disulfide isomerase regions of interaction","volume":"10","author":"Heckler","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2025.118762_bib54","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2210-9-S1-S4","article-title":"Thiol-dependent redox modulation of soluble guanylyl cyclase","volume":"9","author":"Baskaran","year":"2009","journal-title":"BMC Pharm."},{"key":"10.1016\/j.biopha.2025.118762_bib55","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1002\/prot.25096","article-title":"Computational exploration of the binding mode of heme-dependent stimulators into the active catalytic domain of soluble guanylate cyclase","volume":"84","author":"Agull\u00f3","year":"2016","journal-title":"Proteins"},{"key":"10.1016\/j.biopha.2025.118762_bib56","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/sj.emboj.7601521","article-title":"NO and CO differentially activate soluble guanylyl cyclase via a heme pivot-bend mechanism","volume":"26","author":"Ma","year":"2007","journal-title":"EMBO J."},{"key":"10.1016\/j.biopha.2025.118762_bib57","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2210-5-S1-S12","article-title":"Does soluble guanylyl cyclase need a chaperone?","volume":"5","author":"Sun","year":"2005","journal-title":"BMC Pharm."},{"key":"10.1016\/j.biopha.2025.118762_bib58","doi-asserted-by":"crossref","DOI":"10.1096\/fasebj.28.1_supplement.698.9","article-title":"What is the role of S-nitrosation of soluble guanylyl cyclase in the heart? (698.9)","volume":"28","author":"Huang","year":"2014","journal-title":"FASEB J."},{"key":"10.1016\/j.biopha.2025.118762_bib59","article-title":"S-nitrosylation of soluble guanylyl cyclase: a novel mechanism of nitrate tolerance?","volume":"7","author":"Sayed","year":"2007","journal-title":"BMC Pharm."},{"key":"10.1016\/j.biopha.2025.118762_bib60","doi-asserted-by":"crossref","DOI":"10.1021\/bi301518s","article-title":"Correction to inhibition of soluble guanylate cyclase by ODQ","volume":"51","author":"Zhao","year":"2012","journal-title":"Biochemistry"},{"key":"10.1016\/j.biopha.2025.118762_bib61","doi-asserted-by":"crossref","first-page":"9208","DOI":"10.1073\/pnas.1633590100","article-title":"A constitutively activated mutant of human soluble guanylyl cyclase (sGC): implication for the mechanism of sGC activation","volume":"100","author":"Martin","year":"2003","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biopha.2025.118762_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.117829","article-title":"Unveiling the interplay between soluble guanylate cyclase activation and redox signalling in stroke pathophysiology and treatment","volume":"183","author":"Gr\u00f8nning","year":"2025","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.biopha.2025.118762_bib63","article-title":"Receptor guanylyl cyclase (RGC) family in GtoPdb v.2023.1","volume":"2023","author":"Beuve","year":"2023","journal-title":"Iuphar. Bps. Guide Pharm. CITE"},{"key":"10.1016\/j.biopha.2025.118762_bib64","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/eurjhf\/hfs093","article-title":"COMPOSE investigators and coordinators, cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes","volume":"14","author":"Gheorghiade","year":"2012","journal-title":"Eur. J. Heart Fail"},{"key":"10.1016\/j.biopha.2025.118762_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jphs.2024.11.002","article-title":"Different sensitivities of porcine coronary arteries and veins to BAY 60-2770, a soluble guanylate cyclase activator","volume":"157","author":"Tawa","year":"2025","journal-title":"J. Pharm. Sci."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225009564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225009564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T07:01:56Z","timestamp":1777014116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225009564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":65,"alternative-id":["S0753332225009564"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118762","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revisiting soluble guanylate cyclase pharmacology: Additive potential of stimulators and activators","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118762","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118762"}}